1
|
Li Q, Liu M, Wu M, Zhou X, Wang S, Hu Y, Wang Y, He Y, Zeng X, Chen J, Liu Q, Xiao D, Hu X, Liu W. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer. Oncol Lett 2018; 15:5924-5932. [PMID: 29556312 DOI: 10.3892/ol.2018.8075] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 12/11/2017] [Indexed: 12/30/2022] Open
Abstract
Placenta-specific 1 (PLAC1), a novel cancer-testis antigen (CTA), is expressed in a number of different human malignancies. It is frequently produced in breast cancer, serving a function in tumorigenesis. Adoptive immunotherapy using T cell receptor (TCR)-engineered T cells against CTA mediates objective tumor regression; however, to the best of our knowledge, targeting PLAC1 using engineered T cells has not yet been attempted. In the present study, the cDNAs encoding TCRα- and β-chains specific for human leukocyte antigen (HLA)-A*0201-restricted PLAC1 were cloned from a cytotoxic T-lymphocyte, generated by in vitro by the stimulation of CD8+ T cells using autologous HLA-A2+ dendritic cells loaded with a PLAC1-specific peptide (p28-36, VLCSIDWFM). The TCRα/β-chains were linked by a 2A peptide linker (TCRα-Thosea asigna virus-TCRβ), and the constructs were cloned into the lentiviral vector, followed by transduction into human cytotoxic (CD8+) T cells. The efficiency of transduction was up to 25.16%, as detected by PLAC1 multimers. TCR-transduced CD8+ T cells, co-cultured with human non-metastatic breast cancer MCF-7 cells (PLAC1+, HLA-A2+) and triple-negative breast cancer MDAMB-231 cells (PLAC1+, HLA-A2+), produced interferon γ and tumor necrosis factor α, suggesting TCR activation. Furthermore, the PLAC1 TCR-transduced CD8+ T cells efficiently and specifically identified and annihilated the HLA-A2+/PLAC1+ breast cancer cell lines in a lactate dehydrogenase activity assay. Western blot analysis demonstrated that TCR transduction stimulated the production of mitogen-activated protein kinase signaling molecules, extracellular signal-regulated kinases 1/2 and nuclear factor-κB, through phosphoinositide 3-kinase γ-mediated phosphorylation of protein kinase B in CD8+ T cells. Xenograft mouse assays revealed that PLAC1 TCR-transduced CD8+T cells significantly delayed the tumor progression in mice-bearing breast cancer compared with normal saline or negative control-transduced groups. In conclusion, a novel HLA-A2-restricted and PLAC1-specific TCR was identified. The present study demonstrated PLAC1 to be a potential target for breast cancer treatment; and the usage of PLAC1-specific TCR-engineered T cells may be a novel strategy for PLAC1-positive breast cancer treatment.
Collapse
Affiliation(s)
- Qiongshu Li
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China.,Guangdong Provincial Key Laboratory of Cancer Immunotherapy Research and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Muyun Liu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Man Wu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Xin Zhou
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Shaobin Wang
- Interventional and Minimally Invasive Oncology Therapy Department, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518035, P.R. China
| | - Yuan Hu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Youfu Wang
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Yixin He
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Xiaoping Zeng
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Junhui Chen
- Interventional and Minimally Invasive Oncology Therapy Department, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518035, P.R. China
| | - Qubo Liu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Dong Xiao
- Guangdong Provincial Key Laboratory of Cancer Immunotherapy Research and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Xiang Hu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| | - Weibin Liu
- Shenzhen Beike Cell Engineering Research Institute, Shenzhen, Guangdong 518057, P.R. China
| |
Collapse
|
2
|
Tahara Y, Akiyoshi K. Current advances in self-assembled nanogel delivery systems for immunotherapy. Adv Drug Deliv Rev 2015; 95:65-76. [PMID: 26482187 DOI: 10.1016/j.addr.2015.10.004] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2015] [Revised: 09/17/2015] [Accepted: 10/09/2015] [Indexed: 10/24/2022]
Abstract
Since nanogels (nanometer-sized gels) were developed two decades ago, they were utilized as carriers of innovative drug delivery systems. In particular, immunological drug delivery via self-assembled nanogels (self-nanogels) owing to their nanometer size and molecular chaperon-like ability to encapsulate large biomolecules is one of the most well studied and successful applications of nanogels. In the present review, we focus on self-nanogel applications as immunological drug delivery systems for cancer vaccines, cytokine delivery, nasal vaccines, and nucleic acid delivery, including several clinical trials. Cancer vaccines were the first practical application of self-nanogels as vehicles for drug delivery. After successful pre-clinical studies, phase I clinical trials were conducted, and it was found that vaccines consisting of self-nanogels could be administered repeatedly to humans without serious adverse effects, and self-nanogel vaccines induced antigen-specific cellular and humoral immunity. Cytokine delivery via self-nanogels led to the sustained release of IL-12, suppressed tumor growth, and increased Th1-type immune responses. Cationic self-nanogels were effective in penetrating the nasal mucosa and resulted in successful nasal vaccines in mice and nonhuman primates. Cationic self-nanogels were also used for the intracellular delivery of proteins and nucleic acids, and were successfully used to knockdown tumor growth factor expression using short interfering RNA with the immunological effect. These studies suggest that self-nanogels are currently one of the most unique and attractive immunological drug delivery systems and are edging closer to practical use.
Collapse
|